Treatment of Patients with Major Depressive Disorder
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder Third Edition WORK GROUP ON MAJOR DEPRESSIVE DISORDER Alan J. Gelenberg, M.D., Chair Marlene P. Freeman, M.D. John C. Markowitz, M.D. Jerrold F. Rosenbaum, M.D. Michael E. Thase, M.D. Madhukar H. Trivedi, M.D. Richard S. Van Rhoads, M.D., Consultant INDEPENDENT REVIEW PANEL Victor I. Reus, M.D., Chair J. Raymond DePaulo, Jr., M.D. Jan A. Fawcett, M.D. Christopher D. Schneck, M.D. David A. Silbersweig, M.D. This practice guideline was approved in May 2010 and published in October 2010. A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available at http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx. Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST The Work Group on Major Depressive Disorder reports reports receiving honoraria from lectureships for Boeh- the following potentially competing interests for the pe- ringer Ingleheim, Bristol-Myers Squibb, Cyberonics, riod from May 2005 to May 2010: Forest Pharmaceuticals, Inc., Eli Lilly and Company, and Dr. Gelenberg reports consulting for Eli Lilly and Com- Schwartz Pharma. He was involved in the creation of pany, Pfizer, Best Practice, AstraZeneca, Wyeth, Cyber- the Massachusetts General Hospital Psychiatry Academy onics, Novartis, Forest Pharmaceuticals, Inc., GlaxoSmith- (MGH-PA) and has served as a panelist in four satellite Kline, ZARS Pharma, Jazz Pharmaceuticals, Lundbeck, broadcast programs.
[Show full text]